ArticleMolecular medicine (Cambridge, Mass.)2013
Erythropoietin receptor (EpoR) agonism is used to treat a wide range of disease.
Article in Molecular medicine (Cambridge, Mass.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial.BMC cardiovascular disorders · 2017Trial
- Nobiletin: a potential erythropoietin receptor activator protects renal cells against hypoxia.Apoptosis : an international journal on programmed cell death · 2025Article
- Elucidating the Pivotal Neuroprotective Mechanisms and Therapeutic Variants of Erythropoietin in Neonatal Brain Injury.Current topics in medicinal chemistry · 2025Review
- Renal protective effects of helix B surface polypeptide in rats with puromycin aminonucleoside nephropathy.Renal failure · 2024Article
- Microglial EPOR Contribute to Sevoflurane-induced Developmental Fine Motor Deficits Through Synaptic Pruning in Mice.Neuroscience bulletin · 2024Article
- Review
- The effects of normoxic endurance exercise on erythropoietin (EPO) production and the impact of selective βEuropean journal of applied physiology · 2021Article
- Erythropoietin Mediated Bone Loss in Mice Is Dose-Dependent and Mostly Irreversible.International journal of molecular sciences · 2020Article
- The Integrated Landscape of Biological Candidate Causal Genes in Coronary Artery Disease.Frontiers in genetics · 2020Article
- Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms.Journal of neuroinflammation · 2017Article
- Electroacupuncture at GV20 and ST36 Exerts Neuroprotective Effects via the EPO-Mediated JAK2/STAT3 Pathway in Cerebral Ischemic Rats.Evidence-based complementary and alternative medicine : eCAM · 2017Article
- Erythropoietin and a nonerythropoietic peptide analog promote aortic endothelial cell repair under hypoxic conditions: role of nitric oxide.Hypoxia (Auckland, N.Z.) · 2016Article
- Erythropoietin ameliorates hyperglycemia in type 1-like diabetic rats.Drug design, development and therapy · 2016Article
- Low Oxygen Tension Primes Aortic Endothelial Cells to the Reparative Effect of Tissue-Protective Cytokines.Molecular medicine (Cambridge, Mass.) · 2015Article
- New horizons for newborn brain protection: enhancing endogenous neuroprotection.Archives of disease in childhood. Fetal and neonatal edition · 2015Review
- Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection.Pediatric neurology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The erythropoietin receptor (EpoR) was discovered and described in red blood cells (RBCs), stimulating its proliferation and survival. The target in humans for EpoR agonists drugs appears clear-to treat anemia. However, there is evidence of the pleitropic actions of erythropoietin (Epo). For that reason, rhEpo therapy was suggested as a reliable approach for treating a broad range of pathologies, including heart and cardiovascular diseases, neurodegenerative disorders (Parkinson's and Alzheimer's disease), spinal cord injury, stroke, diabetic retinopathy and rare diseases (Friedreich ataxia). Unfortunately, the side effects of rhEpo are also evident. A new generation of nonhematopoietic EpoR agonists drugs (asialoEpo, Cepo and ARA 290) have been investigated and further developed. These EpoR agonists, without the erythropoietic activity of Epo, while preserving its tissue-protective properties, will provide better outcomes in ongoing clinical trials. Nonhematopoietic EpoR agonists represent safer and more effective surrogates for the treatment of several diseases such as brain and peripheral nerve injury, diabetic complications, renal ischemia, rare diseases, myocardial infarction, chronic heart disease and others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.